Any derivative of a non-proteinogenic amino acid resulting from reaction at an amino group or carboxy group, or from the replacement of any hydrogen by a heteroatom.
ChEBI ID: 83812
| Member | Definition | Role |
|---|---|---|
| 3-hydroxynorvaline | A non-proteinogenic amino-acid derivative that is norvaline (2-aminopentanoic acid) in which a hydrogen at position 3 is replaced by a hydroxy group. | 3-hydroxynorvaline |
| ly 404039 | An organic heterobicyclic compound that is (1S,5R)-2-thiabicyclo[3.1.0]hexane carrying oxo, oxo, amino, carboxy, and carboxy groups at positions 2, 2, 4S, 4S, and 6S, respectively. It is a potent agonist of group II metabotropic glutamate receptors mGluR2 mGluR3 (Ki = 149 nM and 92 nM, respectively) and exhibits antipsychotic and anxiolytic efficacy in animal models. | LY404039 |
| n-nitrososarcosine | A nitrosamine that is sarcosine in which the hydrogen attached to the nitrogen has been replaced by a nitroso group. | N-nitrososarcosine |
| n'-formylkynurenine | N-formyl-L-kynurenine zwitterion; N-formyl-L-kynurenine | |
| ucb 34714 | A non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy. | brivaracetam |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 36 (9.63) | 18.7374 |
| 1990's | 22 (5.88) | 18.2507 |
| 2000's | 37 (9.89) | 29.6817 |
| 2010's | 169 (45.19) | 24.3611 |
| 2020's | 110 (29.41) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 65 (16.67%) | 5.53% |
| Reviews | 67 (17.18%) | 6.00% |
| Case Studies | 9 (2.31%) | 4.05% |
| Observational | 8 (2.05%) | 0.25% |
| Other | 241 (61.79%) | 84.16% |